Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AL 01211 (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Fabry's disease; Gaucher's disease type I
  • Focus Adverse reactions; First in man
  • Sponsors AceLink Therapeutics

    • Most Recent Events

    • 26 Feb 2024 According to a AceLink Therapeutics media release, this phase 1 study provided the critical safety and biomarker data to support company ongoing Phase 2 clinical trial in patients with Fabry Disease.
    • 26 Feb 2024 According to a AceLink Therapeutics media release, company announced that the findings from this Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
    • 23 Feb 2023 According to an AceLink Therapeutics media release, positive data from this study were presented at the 2023 WORLD Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top